Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirdametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.67 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirdametinib SCHEMBL172904 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL29358470 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL895854 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| Mirdametinib SCHEMBL29352748 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4859890 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL20435083 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL6295227 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL21067871 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL13667024 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL6292221 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083690-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20250270166-A1 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12275688-B2 | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | SPRINGWORKS THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | claimed |
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | claimed |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-12090128-B2 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | claimed |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-08-22 | — | — | US | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY LLC (US) | 2024-07-16 | — | — | US | claimed |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. | 2024-07-04 | — | — | US | claimed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| EP-1562601-A1 | COMBINATION CHEMOTHERAPY COMPRISING A MEK INHIBITOR AND CAPECITABINE FOR TREATING CANCER | Warner-Lambert Company LLC (US) | 2005-08-17 | — | — | EP | claimed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | claimed |
| WO-2004045617-A1 | COMBINATION CHEMOTHERAPY COMPRISING A MEK INHIBITOR AND CAPECITABINE FOR TREATING CANCER | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | claimed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | claimed |
| CN-1446197-A | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | CN | claimed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275688-B2 | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | NRAS, BRAF, KSR2 | MAP2K1 34/4885MAP2K2 16/4885MAPK1 121/4885 |
| US-20260083690-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | TAS2R5, TAS2R14, TAS2R1 | MAP2K1 1219/4885MAP2K2 861/4885MAPK1 4625/4885 |
| US-20250270166-A1 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF | NRAS, BRAF, KSR2 | MAP2K1 36/4885MAP2K2 17/4885MAPK1 115/4885 |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885MAPK1 4734/4885 |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | VHL, NRAS, KRAS | MAP2K1 3438/4885MAP2K2 3378/4885MAPK1 4542/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885MAPK1 4233/4885 |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | PRKAB2, PRKAB1, PRKAG2 | MAP2K1 51/4885MAP2K2 48/4885MAPK1 698/4885 |
| US-12090128-B2 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof | QDPR, DHFR, NEFM | MAP2K1 4337/4885MAP2K2 3323/4885MAPK1 4873/4885 |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | PDPK1, PLK3, PLK2 | MAP2K1 207/4885MAP2K2 205/4885MAPK1 91/4885 |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | QDPR, DHFR, NEFM | MAP2K1 4337/4885MAP2K2 3323/4885MAPK1 4873/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | MAP2K1 105/4885MAP2K2 89/4885MAPK1 33/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | MAP2K1 12/4885MAP2K2 6/4885MAPK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.